For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Attruby represents a true advancement . These innovative therapies preserve https://attr-cm124209.techionblog.com/42368250/major-attr-cm-advance-the-drug-and-tafamidis-meglumine-offer-promise